ACE, angiotensin I converting enzyme, 1636

N. diseases: 1082; N. variants: 82
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE This study evaluated the potential effect of hydration intensity on the role of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on contrast-induced nephropathy in patients with renal insufficiency. 28490226 2018
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Therefore, we hypothesized that protein hydrolysates from rest raw material from herring and salmon contained ACE inhibiting motifs, and could beneficially affect typical markers for kidney function in an obesity rat model prone to developing renal failure. 29764624 2018
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE We assessed frequency and severity of renal insufficiency in our patients with SSc and estimated the association of renal insufficiency with age, disease duration, subtype of the disease, earlier diagnosed arterial hypertension, and medications for which we assumed to affect renal function-cytostatics, nonsteroidal anti-inflammatory drugs, glucocorticoids, ACE inhibitors, diuretics, and calcium channel blockers (CCB). 28008457 2017
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Angiotensin-converting enzyme inhibition slows, but does not stop, the progression to renal failure; therefore, there is an urgent requirement to expand and intensify research towards discovering new therapeutic targets and new therapies. 27190345 2017
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE This study investigated if the addition of an ACE inhibitor (ACEi) to Ang 1-7 infusion would unmask any beneficial effects of Ang 1-7 on the heart in experimental kidney failure. 28192475 2017
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE The "Expert guidelines for the diagnosis and management of Alport syndrome" recommend treating those with albuminuria with renin-angiotensin-aldosterone system (RAAS) blockade (and adequate birth control because of the teratogenic risks of angiotensin converting enzyme inhibitors), believing that this will delay renal failure. 27287265 2016
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE Influence of angiotensin converting enzyme (<i>ACE</i>) gene rs4362 polymorphism on the progression of kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD). 27748299 2016
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Inhibition of angiotensin-converting enzyme slows progression to kidney failure in patients with Alport syndrome but is not a cure. 24262794 2014
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE Similarly, ACE polymorphism and levels were not related to ventilation-free days (p=0.14 and 0.25, respectively), days without cardiovascular failure (p=0.14 and 0.81, respectively) and days without renal failure (p=0.64 and 0.27, respectively). 22017489 2011
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Angiotensin-converting enzyme inhibitors in native nephropathies reduce proteinuria and delay progression to renal failure. 20061926 2010
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. 16935894 2006
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE We initially evaluated 98 patients with advanced stable CHF who were treated with ACE inhibitors (left ventricular ejection fraction, 28+/-1%; age, 69+/-1 years; 80% male), 10 of whom had an unexplained anemia (normal hematinics and no renal failure). 16172283 2005
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE The associations AGT TT-AT1R AC and CYP11B2 CC-ACE DD showed a possible positive interaction in the development of renal insufficiency among hypertensive subjects. 15662219 2005
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE ACE clades were then determined in patients, and regression methods were used to analyze variables associated with CsA responsivity and progression to renal failure. 16002416 2005
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE The African American Study of Kidney Disease and Hypertension provided evidence that an angiotensin-converting enzyme inhibitor-based treatment program is more beneficial than calcium channel blockers and beta blockers in reducing the progression of renal failure in blacks with hypertensive nephropathy. 14688494 2004
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Genotype DD of the angiotensin-converting enzyme (ACE) is not associated with an increased incidence of native renal diseases, although it could modulate progression to renal failure in patients who already display chronic lesions. 15284309 2004
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE There are conflicting results about the effect of angiotensin-converting enzyme (ACE) gene polymorphism on the progression of renal failure in ADPKD. 14600431 2004
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE We studied retrospectively the role of angiotensinogen (AGT) M235T, angiotensin converting enzyme (ACE) insertion/deletion (I/D), angiotensin II type 1 receptor (AT1R) A1166C, aldosterone syntase (CYP11B2) -344C/T and intron 2 W/C polymorphisms in conjunction with clinical and biochemical covariables on the rate of progression of renal insufficiency in a group of patients with ESRD of various etiologies. 12832734 2003
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE The administration of an angiotensin-converting enzyme (ACE) inhibitor or an oral adsorbent, AST-120 (Kremezin), prevents the progression of renal failure. 11867951 2002
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Most angiotensin-converting enzyme (ACE) inhibitors and their metabolites are excreted renally and doses should hence be reduced in renal insufficiency. 11881130 2001
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE The results in this study in non-diabetic patients with chronic renal disease indicate that the presence of the D allele in the ACE genotype may be of particular importance as a predictor of a high rate of progression in male patients who otherwise do not have a major burden of documented and important prognostic factors for progressive renal insufficiency. 10727542 2000
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE ACE or AT1R, may affect the progression to renal failure of patients (especially females) with NIDDM. 10364706 1999
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 Biomarker disease BEFREE Furthermore, a number of trials have shown that ACE-inhibitors (ACEi) may reduce the rate of progression of renal failure. 10202997 1999
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. 10430974 1999
CUI: C0035078
Disease: Kidney Failure
Kidney Failure
0.400 GeneticVariation disease BEFREE It remains to be clarified by multi-center analysis using large numbers of patients whether the gene polymorphism of ACE is related to the progression of diabetic nephropathy to renal failure. 9350677 1997